PAUL WARREN SHABRAM
Pilots at Peppertree Ln, Encinitas, CA

6464976, Oct 15, 2002

Aug 31, 2000

09/653474

Drake M. LaFace - San Diego CA
Amena Rahman - San Diego CA
Paul W. Shabram - Olivenhain CA
Van T. Tsai - San Diego CA

Canji, Inc. - San Diego CA

A61K 3900

4241401, 4242331, 4241311, 4241591, 4242781, 424 931, 435 71, 530351, 514885, 604 401, 604 501, 604 502

The present invention provides an apparatus and method to diminish the pre-existing immune response to the administration of a therapeutic virus by the selective elimination of antiviral antibodies from the serum. The present invention provides a chromatographic material for the elimination of such antibodies. The invention further provides plasmapheresis apparatus comprising this material. The invention further provides methods for the employment of such apparatus as part of therapeutic treatment regiments.

2002015, Oct 17, 2002

Jan 30, 2002

10/062216

Muralidhara Ramachandra - San Diego CA, US
Paul Shabram - Olivenhain CA, US

A61K048/00, C12N015/861

424/093200, 424/456000, 435/320100

The present invention provides recombinant viruses which replicate the viral genome selectively in response to the intracellular conditions of the target cell through the use a pathway-responsive promoter which substantially inhibits viral replication in the host cell based on the phenotypic or genotypic of the infected cell. In the target cell, the promoter element of the pathway-responsive promoter is inactive and thus the virus is permitted to replicate. This results in: (1) killing the cells by natural lytic nature of the virus, and/or (2) provides a therapeutic dose of a transgene product (amplified in comparison to replication incompetent vectors) to the target cell, and (3) producing a localized concentration of the virus facilitating the infection of surrounding cells to the recombinant virus. The invention further provides therapeutic and diagnostic methods of use of the vectors, pharmaceutical formulations comprising the vectors, methods of making the vectors and transformed cells comprising the vectors.

5994134, Nov 30, 1999

May 4, 1998

9/073076

Daniel D. Giroux - La Jolla CA
Ann M. Goudreau - San Diego CA
Muralidhara Ramachandra - San Diego CA
Paul W. Shabram - Olivenhain CA

Canji, Inc. - San Diego CA

C12N 701

435403

The present invention is directed to a method of producing recombinant viral vectors at high titers incorporating a variety of important advancements over the art. The method of the present invention incorporates multiple features which provide enhanced production of viruses, particularly those viruses encoding exogenous transgenes. The specifically illustrated method describes a method for the high titer serum-free media production of recombinant replication defective adenoviruses containing an exogenous transgene. The invention provides methods of preparing microcarriers, methods for seeding bioreactors at high cell density, increasing the infectivity of the producer cells to the virus, methods to increase product yield through synchronization of the cell cycle of the producer cells, and methods to minimize the deleterious effects of exogenous transgenes. The invention further provides producer cells prepared by the process of the invention. The invention further provides viruses produced by the process.

8133481, Mar 13, 2012

Feb 16, 2010

12/706134

Muralidhara Ramachandra - San Diego CA, US
Paul W. Shabram - Olivenhain CA, US

Canji, Inc. - Palo Alto CA

A01N 63/00, A61K 35/713, A61K 48/00, C07H 21/04, C12N 15/00, C12N 15/12, C12N 15/34

424 936, 424 931, 4353201, 435325, 536 234, 514 44

The present invention provides recombinant viruses which replicate the viral genome selectively in response to the intracellular conditions of the target cell through the use a pathway-responsive promoter which substantially inhibits viral replication in the host cell based on the phenotypic or genotypic of the infected cell. In the target cell, the promoter element of the pathway-responsive promoter is inactive and thus the virus is permitted to replicate. This results in: (1) killing the cells by natural lytic nature of the virus, and/or (2) provides a therapeutic dose of a transgene product (amplified in comparison to replication incompetent vectors) to the target cell, and (3) producing a localized concentration of the virus facilitating the infection of surrounding cells to the recombinant virus. The invention further provides therapeutic and diagnostic methods of use of the vectors, pharmaceutical formulations comprising the vectors, methods of making the vectors and transformed cells comprising the vectors.

7001770, Feb 21, 2006

Oct 13, 1999

09/416735

Isabella A. Atencio - San Diego CA, US
Drake M. LaFace - San Diego CA, US
Muralidhara Ramachandra - San Diego CA, US
Paul W. Shabram - Olivenhain CA, US

Canji, Inc. - San Diego CA

C12N 15/00, C12N 15/63, C12N 15/85, C12N 15/86

435455, 435440, 435456

The present invention provides a method to enhance apoptosis in a cell by the administration of p53 in combination with a calpain inhibitor. The present invention provides a method of increasing the infectivity of a cell to a viral vector by treatment of the cell with a calpain inhibitor. the present invention further provides a method of enhancing transciption of a therapeutic transgene from the CMV promoter. The present invention also provides a method of suppress the in vivo CTL response to viral vectors by the use of calpain inhibitors. The present invention further provides a pharmaceutical formulations of p53 and a calpain inhibitor in a pharmaceutically acceptable carrier. The present invention provides a method of ablating neoplastic cells in a mammalian organism in vivo by the co-administration of a calpain inhibitor and p53. The present invention also provides a method of ablating neoplastic cells in a population of normal cells contaminated by said neoplastic cells ex vivo by the administration of a recombinant adenovirus in combination with a calpain inhibitor to said population.

5837520, Nov 17, 1998

Mar 7, 1995

8/400793

Paul W. Shabram - Olivenhain CA
Bernard G. Huyghe - San Diego CA
Xiaodong Liu - New York NY
H. Michael Shepard - Rancho Santa Fe CA

Canji, Inc. - San Diego CA

C12N 702, C12N 700, C12N 1500

435239

The invention provides a method for purifying viral vectors containing therapeutic genes for use in gene therapy. The invention comprises a method of purification from a cell lysate of a recombinant viral vector containing a therapeutic gene, which comprises: a) treating said lysate with an enzymatic agent that selectively degrades both unencapsulated DNA and RNA; b) chromatographing the treated lysate from step a) on a first resin; and c) chromatographing the eluant from step b) on a second resin; wherein one resin is an anion exchange resin and the other is an immobilized metal ion chromatography (IMAC) resin.

2002018, Dec 12, 2002

Aug 16, 2002

10/222722

Drake LaFace - San Diego CA, US
Amena Rahman - San Diego CA, US
Paul Shabram - Olivenhain CA, US
Van Tsai - San Diego CA, US

A61K039/395, A61K039/00, C07H021/04, C12N015/00, C12N015/09, C12N015/63, C12N015/70, C12N015/74

424/140100, 435/320100, 536/023720

The present invention provides an apparatus and method to diminish the pre-existing immune response to the administration of a therapeutic virus by the selective elimination of antiviral antibodies from the serum. The present invention provides a chromatographic material for the elimination of such antibodies. The invention further provides plasmapheresis apparatus comprising this material. The invention further provides methods for the employment of such apparatus as part of therapeutic treatment regiments.